Egalet Corp. has entered into a definitive collaboration and license agreement with Shionogi Ltd. for the development and potential commercialization of multiple oral abuse-deterrent hydrocodone opioid product candidates using Egalet’s technology platform. Egalet will receive $10 million upfront and is eligible to receive milestone payments of as much as $300 million for development and approval of products under the agreement, as well as royalties on sales that could exceed $100 million....